Quick Answer
SUTRO BIOPHARMA, INC. reported R&D Expense of $166.42 million for fiscal year 2025.
SUTRO BIOPHARMA, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $166.42M | -34.0% |
| 2024 | $252.04M | +39.7% |
| 2023 | $180.43M | +31.5% |
| 2022 | $137.17M | +31.4% |
| 2021 | $104.40M | +35.7% |
| 2020 | $76.96M | +17.3% |
| 2019 | $65.61M | +20.9% |
| 2018 | $54.26M | -0.7% |
| 2017 | $54.64M | +25.5% |
| 2016 | $43.55M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $39.85M | -35.8% | +4.0% |
| June 30, 2025 | $38.33M | -38.2% | -25.7% |
| March 31, 2025 | $51.60M | -9.3% | -16.9% |
| September 30, 2024 | $62.11M | +36.0% | +0.1% |
| June 30, 2024 | $62.02M | +49.1% | +9.0% |
| March 31, 2024 | $56.88M | +44.4% | +24.5% |
| September 30, 2023 | $45.67M | +44.0% | +9.8% |
| June 30, 2023 | $41.59M | +28.6% | +5.6% |
- SUTRO BIOPHARMA, INC. showed a decrease of -34.0% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, SUTRO BIOPHARMA, INC.’s r&d expense has grown by 282.1% (from $43.55 million to $166.42 million).
- The most recent figure is from SUTRO BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: